Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026
Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Fineline Cube Aug 12, 2026
Company Deals

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Fineline Cube Aug 12, 2026
Company Deals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Fineline Cube Aug 12, 2026
Company Deals

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Fineline Cube Aug 12, 2026
Company Drug

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Fineline Cube Aug 12, 2026
Company Deals

ImmuneOnco Receives $10M Milestone Payment from Instil Bio for IMM2510/IMM27M Collaboration

Fineline Cube Jul 31, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced today that it has received a...

Company Deals

Luoxin Pharmaceutical Transfers Equity Stake to Shanghai Pharma for RMB 415 Million

Fineline Cube Jul 31, 2025

China-based Luoxin Pharmaceutical Group Co., Ltd. (SHE: 002793) announced that its subsidiary, Shandong Luoxin Pharmaceutical...

Company Deals

Sino Biopharmaceutical on Track to Receive $300M Milestone Payment for PD-1/VEGF Antibody Deal

Fineline Cube Jul 31, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the out-licensing collaboration between its subsidiary...

Company Deals

Walvax Expands Rights to Notitia’s Gut Microbiota Therapy in Greater China

Fineline Cube Jul 31, 2025

Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that an amendment...

Company Drug

Sanofi’s SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma

Fineline Cube Jul 31, 2025

French pharmaceutical major Sanofi (NASDAQ: SNY) reported that the U.S. Food and Drug Administration (FDA)...

Company Deals

Sandoz to Acquire Evotec’s Biologics Unit for $300 Million Expansion

Fineline Cube Jul 31, 2025

Switzerland-headquartered Sandoz (SWX: SDZ) announced that it has signed a non-binding term sheet with Germany’s...

Company Drug

Zhaoke Ophthalmology’s Melphalan Granted FDA Orphan Drug Designation for Pediatric Retinoblastoma

Fineline Cube Jul 31, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622), a leader in ophthalmic solutions, today announced that its...

Company Deals

Zhaoke Ophthalmology Partners with French FAREVA for Strategic Expansion

Fineline Cube Jul 31, 2025

China-based Zhaoke Ophthalmology (HKG: 6622) announced the signing of a Memorandum of Agreement (MOA) with...

Company Deals

Lee’s Pharma Partners with Shaohe Biotech to Translate Probiotics into Public Health Solutions

Fineline Cube Jul 31, 2025

China-based Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced on July 28, 2025, that it has...

Company

GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines

Fineline Cube Jul 31, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) released its Q2 and H1 2025 financial results. Q2 sales...

Company Deals

CSPC Signs Exclusive Licensing Deal with Madrigal for GLP-1 Agonist SYH2086

Fineline Cube Jul 31, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced today that it has entered into an...

Company Drug

HRAIN Biotech’s HICARA Approved by NMPA for Relapsed/Refractory LBCL

Fineline Cube Jul 31, 2025

The National Medical Products Administration (NMPA) officially approved the New Drug Application (NDA) for lenecabtagene...

Company Drug

Eli Lilly’s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial

Fineline Cube Jul 30, 2025

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on July 29, 2025, that...

Company Drug

Shanghai Pharmaceuticals’ B019 Injection Approved for SLE Clinical Trials

Fineline Cube Jul 30, 2025

Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) announced that it has received...

Company Drug

Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment

Fineline Cube Jul 30, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing...

Company Deals

LTZ Therapeutics and Eli Lilly Partner to Develop Myeloid Engager Therapeutics

Fineline Cube Jul 30, 2025

LTZ Therapeutics and Eli Lilly (NYSE: LLY) announced a significant strategic collaboration on July 29,...

Company Drug

Huadong Medicine Receives NMPA Approval for Phase III Trial of Psoriasis Cream MC2-01

Fineline Cube Jul 30, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...

Others

China Medical System’s ZUNVEYL NDA Accepted by China’s NMPA for Alzheimer’s Treatment

Fineline Cube Jul 30, 2025

China Medical System Holdings Ltd (CMS; HKG: 0867, SGX: 8A8) announced on July 28, 2025,...

Company

MSD’s Q2 Earnings Hit by Gardasil Sales Decline, Keytruda Growth Slows

Fineline Cube Jul 30, 2025

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced its Q2 2025 financial results,...

Company

Novo Nordisk Shares Plummet 20% as Obesity Drug Competition Intensifies and Full-Year Guidance Lowered

Fineline Cube Jul 30, 2025

Shares of Denmark-based biopharma giant Novo Nordisk A/S (NYSE: NVO) dipped over 20% during trading...

Posts pagination

1 … 162 163 164 … 707

Recent updates

  • Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal
  • NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib
  • Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million
  • Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026
  • Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal

Company Medical Device

NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.